Literature DB >> 1692885

Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.

W H Cooner1, B R Mosley, C L Rutherford, J H Beard, H S Pond, W J Terry, T C Igel, D D Kidd.   

Abstract

The prostate cancer detection rate from screening by digital rectal examination and tactilely guided prostate biopsy is approximately 1.7%. Among 1,807 men a detection rate of 14.6% was achieved in a clinical urological practice by physician-conducted prostate ultrasonography, digital rectal examination and determination of serum prostate specific antigen. Results are presented in 5-year increments as well as for the group as a whole. The possible benefit to be derived from an improved detection rate is undetermined. Recommendations are made regarding the clinical use of these diagnostic modalities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692885     DOI: 10.1016/s0022-5347(17)40211-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  80 in total

1.  Improving diagnostic accuracy of prostate carcinoma by systematic random map-biopsy.

Authors:  J Szabó; G Hegedûs; K Bartók; T Kerényi; A Végh; I Romics; B Szende
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Knowledge, attitudes, and screening practices among older men regarding prostate cancer.

Authors:  C B Steele; D S Miller; C Maylahn; R J Uhler; C T Baker
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 3.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

Review 4.  [Multiparametric MRI, elastography, contrastenhanced TRUS. Are there indications with reliable diagnostic advantages before prostate biopsy?].

Authors:  A Hegele; L Skrobek; R Hofmann; P Olbert
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

5.  Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy.

Authors:  Athanasios N Argyropoulos; Konstantinos Doumas; Antonios Farmakis; Ioannis Liakatas; Ioannis Gkialas; Michael Lykourinas
Journal:  Int Urol Nephrol       Date:  2007-01-04       Impact factor: 2.370

6.  Does the level of prostate cancer risk affect cancer prevention with finasteride?

Authors:  Ian M Thompson; Catherine M Tangen; Howard L Parnes; Scott M Lippman; Charles A Coltman
Journal:  Urology       Date:  2008-05       Impact factor: 2.649

7.  Usefulness of aspiration cytology in prostate cancer detection.

Authors:  H Ito; K Yamaguchi; T Kotake; O Matsuzaki; K Nagao
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 8.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

9.  Prostate cancer screening--a physician survey in Missouri.

Authors:  D A Lawson; E J Simoes; D Sharp; T Murayi; R Hagan; R C Brownson; J Wilkerson
Journal:  J Community Health       Date:  1998-10

10.  Metastatic prostate cancer with normal level of serum prostate-specific antigen.

Authors:  R Nishio; Y Furuya; O Nagakawa; H Fuse
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.